Logos Global Management LP Has $7 Million Stock Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

Logos Global Management LP increased its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 349.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,159,030 shares of the company’s stock after buying an additional 901,050 shares during the period. Logos Global Management LP’s holdings in COMPASS Pathways were worth $7,001,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in COMPASS Pathways during the 4th quarter valued at about $33,000. Blue Trust Inc. acquired a new position in COMPASS Pathways during the 2nd quarter worth approximately $81,000. Kennedy Capital Management LLC acquired a new position in COMPASS Pathways during the 1st quarter worth approximately $139,000. Tidal Investments LLC boosted its holdings in shares of COMPASS Pathways by 43.6% in the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after buying an additional 5,795 shares during the last quarter. Finally, Chesapeake Capital Corp IL acquired a new stake in shares of COMPASS Pathways in the 1st quarter valued at approximately $189,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Down 3.7 %

CMPS stock opened at $6.98 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.03 and a quick ratio of 12.03. The stock has a market capitalization of $477.30 million, a price-to-earnings ratio of -2.95 and a beta of 2.27. The business’s fifty day moving average price is $7.21 and its two-hundred day moving average price is $7.75. COMPASS Pathways plc has a fifty-two week low of $5.01 and a fifty-two week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same period in the previous year, the company posted ($0.62) earnings per share. On average, equities analysts anticipate that COMPASS Pathways plc will post -2.35 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on CMPS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $23.00 price target on shares of COMPASS Pathways in a report on Tuesday, September 10th. Canaccord Genuity Group cut their price target on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a report on Friday, August 23rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.